Plasma biomarkers for dementia are blood tests that detect protein changes associated with Alzheimer’s disease and other dementias years before memory loss appears. These tests measure molecules like phosphorylated tau (p-tau), amyloid-beta, and neurofilament light chain in blood plasma—the same abnormalities found in cerebrospinal fluid or visible on expensive PET brain scans, but without the invasiveness or cost. A 65-year-old woman with a family history of Alzheimer’s can now take a simple blood test to learn whether pathological changes are already underway in her brain, giving her and her physician time to consider lifestyle interventions or future treatment options.
The shift from specialized brain imaging to blood testing represents one of the most significant advances in dementia diagnostics in decades. For most of their history, dementia evaluations relied on cognitive testing, MRI or CT scans to rule out strokes or tumors, and sometimes spinal taps to measure biomarkers in cerebrospinal fluid. Plasma biomarker tests—sometimes called “liquid biopsies”—change this equation: they are fast, widely available at routine labs, relatively inexpensive, and increasingly supported by FDA clearances and clinical practice guidelines.
Table of Contents
- What Are Plasma Biomarkers and Which Ones Matter Most?
- How the Testing Actually Works and What It Measures
- FDA Clearances and Current Clinical Status
- Accuracy, Sensitivity, and What the Numbers Really Mean
- Comparison to CSF Testing and PET Imaging
- Recent Clinical Trial Data and Emerging Treatments
- Practical Limitations and When to Order These Tests
What Are Plasma Biomarkers and Which Ones Matter Most?
Plasma biomarkers are proteins and other molecules in blood that reflect disease processes in the brain. The most clinically useful ones for dementia detection fall into several categories. Phosphorylated tau (especially p-tau181 and p-tau217) accumulates in Alzheimer’s disease and is now considered a hallmark of Alzheimer’s pathology. Amyloid-beta 42 (Aβ42) is depleted in Alzheimer’s brains and often reduced in blood as the disease develops.
Neurofilament light chain (NfL) is a marker of neurodegeneration—it rises when neurons are damaged or dying, and high levels suggest more advanced brain pathology or faster cognitive decline. More recent biomarkers include glial fibrillary acidic protein (GFAP), which reflects activation of astrocytes (support cells in the brain) during Alzheimer’s pathology, and phosphorylated tau variants (p-tau181, p-tau217, p-tau239) that differ in their ability to predict amyloid and tau PET positivity. A research team at Washington University published data showing that plasma p-tau217 is slightly more sensitive than p-tau181 for detecting tau pathology on PET imaging. Unlike a single score, clinicians often order panels of multiple biomarkers to build a fuller picture—much like how a blood lipid panel measures cholesterol, triglycerides, and HDL together rather than relying on one number.
How the Testing Actually Works and What It Measures
A plasma biomarker test requires a standard blood draw into a tube, usually collected at a routine lab or doctor’s office. The sample is sent to a clinical laboratory equipped with specialized equipment—typically mass spectrometry or immunoassay platforms—that measure the concentration of specific proteins. The entire process takes minutes to perform and hours to process; results are usually returned within days to a week. There are no fasting requirements, no special preparation, and no more discomfort than a routine blood draw. The critical limitation is interpretation: plasma biomarkers tell you whether Alzheimer’s pathology is present in the brain, but they do not diagnose dementia or predict when cognitive symptoms will appear.
A person can have positive biomarkers (amyloid and tau pathology in the brain) for 10, 15, or 20 years before showing any memory problems. This is called “asymptomatic Alzheimer’s disease” or “preclinical Alzheimer’s pathology,” and it exists on a spectrum. Additionally, biomarker levels can be affected by genetics, age, kidney function, and other factors. An elevated NfL, for instance, can indicate several conditions beyond Alzheimer’s—frontotemporal dementia, Lewy body disease, or even recent stroke. This is why biomarkers are meant to support clinical judgment, not replace it.
FDA Clearances and Current Clinical Status
As of 2024, the FDA has cleared several plasma biomarker tests for clinical use. The Elecsys Phospho-Tau (p-tau181) test received FDA clearance in 2022 for detecting amyloid and tau pathology in cognitively normal individuals or those with mild cognitive impairment. The LumipulseG p-tau217 assay also carries FDA clearance. These are not tests that diagnose Alzheimer’s disease itself; instead, they detect underlying pathology—Alzheimer’s disease is ultimately diagnosed during life based on cognitive symptoms plus biomarkers, or confirmed through autopsy after death.
Major medical organizations including the Alzheimer’s Association and American Academy of Neurology have incorporated plasma biomarkers into clinical practice guidelines. They are now recommended as part of the evaluation of anyone with cognitive complaints or family history of dementia. Insurance coverage varies: Medicare covers plasma biomarker testing for individuals with cognitive concerns, though copays may apply. Private insurers’ policies differ, and some patients must pay out of pocket, typically $300 to $1,000 depending on which biomarkers are measured.
Accuracy, Sensitivity, and What the Numbers Really Mean
Published studies show that plasma p-tau217 has roughly 90% sensitivity and 85% specificity for detecting brain amyloid pathology when compared to amyloid PET imaging—meaning it correctly identifies 9 out of 10 people who have amyloid buildup and correctly identifies 85 out of 100 people who do not. Plasma p-tau181 is slightly less sensitive (around 85% for amyloid detection) but remains highly useful. These are strong numbers compared to cognitive testing alone, which often misses early pathology. The tradeoff is that plasma biomarkers cannot yet predict individual risk as accurately as we would like.
If your p-tau217 is elevated, we know you have pathology, but we cannot say whether you will develop dementia in 5 years, 10 years, or never. Studies following cognitively normal biomarker-positive individuals show that elevated biomarkers and faster cognitive decline correlate over 2-5 year follow-ups, but the correlation is not tight enough for individual prediction. An 80-year-old with positive biomarkers and excellent cognition may never show decline. A 65-year-old with the same biomarker results might experience accelerating memory loss over the next decade. Age, genetics, cognitive reserve, and vascular health all influence who converts to symptomatic disease and who remains stable.
Comparison to CSF Testing and PET Imaging
Lumbar puncture to collect cerebrospinal fluid (CSF) was historically the only biological way to measure Alzheimer’s biomarkers before death. CSF biomarkers—low Aβ42, high phosphorylated tau, and high total tau—are highly specific and sensitive for Alzheimer’s pathology. However, lumbar puncture carries small risks of infection, headache, and bleeding, and many patients and physicians are reluctant to perform it for screening. It is primarily reserved for uncertain diagnostic cases or research studies. PET imaging (positron emission tomography) directly visualizes amyloid and tau pathology in the brain with excellent spatial resolution.
A neurologist can see exactly where pathology is located and how severe it is. However, PET is expensive ($3,000-$5,000 per scan, often not covered by insurance), requires specialized scanners and radiologists, and involves radiation exposure. Plasma biomarkers are far cheaper, faster, and safer, making them practical for initial screening. The tradeoff is that they give a blood-level answer (do you have pathology? how much?) without telling you where in the brain the pathology concentrates. Many clinicians now use plasma tests as a first filter: if biomarkers are negative, expensive PET imaging is unlikely to be needed. If biomarkers are positive, PET imaging may follow for more detailed information or to rule out alternative diagnoses.
Recent Clinical Trial Data and Emerging Treatments
The connection between plasma biomarkers and treatment has accelerated over the past two years. Lecanemab (Leqembi) and donanemab (Kisunla) are monoclonal antibodies that target amyloid and slow cognitive decline in people with amyloid pathology and mild cognitive impairment or mild dementia. These drugs require biomarker confirmation of amyloid positivity before starting—either through plasma biomarkers, amyloid PET, or CSF testing.
Lecanemab infusion studies and clinical trials tracked plasma p-tau and NfL levels as secondary measures of drug response. Emerging data suggests that plasma biomarkers, particularly NfL, may predict which patients respond best to anti-amyloid therapy and whether the drug is slowing disease progression. Ongoing trials are testing combination therapies pairing anti-amyloid drugs with anti-tau agents, again using plasma biomarkers to select participants and monitor response. The field is moving toward a model in which plasma biomarkers stratify risk and guide treatment selection much earlier than before—even in people without cognitive symptoms.
Practical Limitations and When to Order These Tests
Ordering a plasma biomarker panel makes sense for a cognitively normal person with a strong family history of early-onset dementia, significant cognitive complaints, or results from cognitive screening tests that suggest decline. It is less useful in someone with advanced dementia; the diagnosis is already apparent, and knowing amyloid and tau status does not immediately change management. A major limitation is the interpretation burden on patients: many people receive results showing “positive biomarkers” without clear understanding of what this means for their future or what, if anything, they should do about it.
Plasma biomarkers are most valuable when combined with cognitive testing, MRI (to rule out stroke or tumor), and discussion of lifestyle factors—sleep, exercise, cognitive engagement, cardiovascular health, and social connection all influence dementia risk. A positive plasma biomarker is a signal for more aggressive lifestyle intervention, closer neurological follow-up, and earlier consideration of disease-modifying therapies. A negative biomarker in someone with subjective cognitive complaints may reassure the patient but does not rule out other causes of memory problems or the possibility of non-Alzheimer’s dementia. In clinical practice, biomarkers inform rather than dictate decisions, and they work best when physicians discuss results in person with patients and families.
- —
